Regulatory – Page 12 – Alligator Bioscience

2019-04-17

Regulatory

Alligator Bioscience AB (publ) Interim report January-March 2019

First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...

2019-04-10

Regulatory

Tumor-localizing properties of bispecific antibody demonstrated by live imaging Lund, Sweden, April 10, 2019 – Alligator Bioscience (Nasdaq ...

2019-04-02

Regulatory

Lund, Sweden, April 2, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ...

2019-03-22

Regulatory

Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2019-03-18

Regulatory

Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for th ...

2019-03-07

Regulatory

Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody Lund, Sweden, March 7, 2019 – Alligator Bioscience (Nasdaq St ...

2019-02-14

Regulatory

The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...

2018-12-11

Regulatory

A first-in-class bispecific CTLA-4 antibody Lund, Sweden, December 11, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announ ...

2018-11-09

Regulatory

Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cance ...